News

Open calls for transnational and/or virtual open access to European research infrastructures

Published on | 1 month ago

Programmes
Research Infrastructures Health Culture and society Civil Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment

More information is available about opportunities for transnational (TNA) and virtual access (VA) to European research infrastructures for researchers from the academic and private sector in this RICH Europe leaflet. Access the database on TNA and VA open calls here. The database can be filtered on scientific domain, the status of the call (open, closed, forthcoming), type of access and project acronym. Currently there are several open calls for TNA and/or VA. More information is available via the links below.

For any questions about the calls, please contact the infrastructures directly.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

2037 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.